Isopropylethanediol (IPED) is a colorless, odorless, viscous liquid with a sweet taste. It is a synthetic compound, not found naturally, and is primarily produced through a chemical reaction between acetone and ethylene glycol. IPED is a humectant, meaning it attracts and retains moisture. This property makes it a common ingredient in cosmetics, personal care products, and pharmaceuticals. It is also used as a solvent in various industrial applications. IPED is generally considered safe for topical use, but ingestion can lead to adverse health effects. Research on IPED primarily focuses on its applications in cosmetics and pharmaceuticals, as well as its potential toxicity and environmental impact. For example, studies have examined its effectiveness as a moisturizer, its potential to cause skin irritation, and its biodegradability.'
isopropylethanediol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 7996 |
| CHEMBL ID | 3187409 |
| SCHEMBL ID | 165976 |
| MeSH ID | M0051848 |
| Synonym |
|---|
| LS-13096 |
| inchi=1/c5h12o2/c1-5(2)7-4-3-6/h5-6h,3-4h2,1-2h |
| isopropoxyethanol |
| 2-(1-methylethoxy)ethanol |
| hsdb 2831 |
| isopropylethylene glycol ether |
| nsc 1259 |
| isopropyl glycol |
| einecs 203-685-6 |
| beta-hydroxyethyl isopropyl ether |
| isopropylethanediol |
| ai3-03871 |
| ethylene glycol, monoisopropyl ether |
| iso-propyl glycol ether |
| brn 1732184 |
| ucar ac |
| dowanal eipat |
| wln: q2oy1 & 1 |
| ethylene glycol isopropyl ether |
| dowanol eipat |
| isopropyl cellosolve |
| .beta.-hydroxyethyl isopropyl ether |
| ethanol, 2-isopropoxy- |
| nsc-1259 |
| ethanol, 2-(1-methylethoxy)- |
| monoisopropyl ether of ethylene glycol |
| ethylene glycol monoisopropyl ether |
| 2-isopropoxyethanol , |
| isopropyl oxitol |
| nsc1259 |
| 109-59-1 |
| 2-isopropoxyethanol, 99% |
| 2-propan-2-yloxyethanol |
| E0110 |
| AKOS000120277 |
| NCGC00248303-01 |
| unii-9l4rl5ekzc |
| ec 203-685-6 |
| 9l4rl5ekzc , |
| dtxsid4047466 , |
| dtxcid2027466 |
| cas-109-59-1 |
| tox21_301136 |
| NCGC00255035-01 |
| FT-0626332 |
| isopropylglycol |
| SCHEMBL165976 |
| 2-((1-methylethyl)oxy)ethanol |
| 2-isopropyloxyethanol |
| isopropoxyethanol [hsdb] |
| 2-(isopropyloxy)ethanol |
| 2-isopropoxy-ethanol |
| 2-[(1-methylethyl)oxy]ethanol |
| 2-isopropoxy ethanol |
| 2-(propan-2-yloxy)ethanol |
| 2-isopropoxy-1-ethanol |
| ethylene glycol monoisopropyl |
| ethylene glycol monisopropyl ether |
| 4-methyl-3-oxa-1-pentanol |
| W-109400 |
| CHEMBL3187409 |
| mfcd00002866 |
| 2-isopropoxyethanol; 98% |
| Q15632912 |
| F93017 |
| EN300-20504 |
| 2-(propan-2-yloxy)ethan-1-ol |
| Z104478444 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| progesterone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0004 | 17.9460 | 75.1148 | AID1346784 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.4364 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 76.9588 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||